triazoles has been researched along with Chronic Kidney Diseases in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.86) | 29.6817 |
| 2010's | 21 (60.00) | 24.3611 |
| 2020's | 13 (37.14) | 2.80 |
| Authors | Studies |
|---|---|
| Akizawa, T; Hayasaki, T; Hayashi, Y; Matsuda, Y; Nobori, K; Yamamoto, H | 3 |
| Akizawa, T; Fujikawa, R; Fujioka, M; Nagao, Y | 1 |
| Hartner, A; Schley, G | 1 |
| Fukui, K; Nangaku, M; Saito, H; Sugahara, M; Tanaka, T; Uchida, L; Wakashima, T | 1 |
| Markham, A | 1 |
| Agoro, R; Allen, MR; Atkins, GJ; Broxmeyer, HE; Capitano, ML; Clinkenbeard, EL; Ni, P; Noonan, ML; Prideaux, M; Sacks, SA; Swallow, EA; Thompson, WR; Wheeler, JA; White, KE | 1 |
| Kitada, K; Kittikulsuth, W; Konishi, Y; Morikawa, T; Morisawa, N; Nakano, D; Nishiyama, A; Rahman, A; Zhang, A | 1 |
| Babickova, J; Chen, T; Elsaid, H; Furriol, J; Gausdal, G; Hoel, A; Hoel, F; Landolt, L; Lorens, JB; Marti, HP; Osman, T; Tronstad, KJ | 1 |
| Akizawa, T; Hayasaki, T; Hayashi, Y; Matsuda, Y; Nobori, K; Taki, K; Yamamoto, H | 1 |
| Akizawa, T; Hirakata, H; Koretomo, R; Maeda, K; Nangaku, M; Yamada, O; Yamaguchi, T | 1 |
| Fukui, K; Nangaku, M; Tanaka, T | 1 |
| Chen, Z; Zhao, H; Zhou, L; Zhu, L | 1 |
| Arens, ER; Böttcher, M; Kaiser, A; Kubitza, D; Lentini, S; Thuss, U; van der Mey, D; Wensing, G | 1 |
| Akizawa, T; Arai, M; Hirakata, H; Koretomo, R; Matsui, A; Nangaku, M; Yamaguchi, T | 1 |
| Akizawa, T; Bernhardt, T; Berns, JS; Iekushi, K; Krueger, T; Macdougall, IC; Staedtler, G; Taguchi, M | 1 |
| Akizawa, T; Arai, M; Hirakata, H; Koretomo, R; Maeda, K; Miyazawa, Y; Nangaku, M; Yamaguchi, T | 1 |
| Akizawa, T; Iekushi, K; Matsuda, Y; Taguchi, M; Yamada, T; Yamamoto, H | 2 |
| Akizawa, T; Bernhardt, T; Berns, JS; Iekushi, K; Macdougall, IC; Taguchi, M; Yamamoto, H | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Bain, SC; Eligar, VS | 1 |
| Aguiar, CF; Andrade-Oliveira, V; Braga, TT; Câmara, NO; Castoldi, A; Correa-Costa, M; Hiyane, MI; Jancar, S; Malheiros, DM; Origassa, CS; Rios, FJ; Rodas, AC | 1 |
| Díaz-García, JD; Gallegos-Villalobos, A; Gonzalez-Espinoza, L; Ortiz, A; Sanchez-Niño, MD; Villarrubia, J | 1 |
| Chen, CH; Shu, KH; Yang, Y | 1 |
| Ellinghaus, P; Flamme, I; Jeske, M; Keldenich, J; Oehme, F; Thuss, U | 1 |
| Eguchi, A; Fujii, A; Hirotani, S; Iwasaku, T; Masuyama, T; Morisawa, D; Naito, Y; Oboshi, M; Okuhara, Y; Sawada, H | 1 |
| Kumagai, H; Matsubara, H; Nishida, Y; Onimaru, H; Oshima, N; Takechi, H; Uchida, T; Watanabe, A | 1 |
| Chung, BH; Jin, L; Lim, SW; Piao, SG; Yang, CW | 1 |
| Gupta, N; Wish, JB | 1 |
| Amatruda, JM; Arjona Ferreira, JC; Chan, JC; Davies, MJ; Gonzalez, E; Kaufman, KD; Scott, R; Sheng, D; Stein, PP; Williams-Herman, D | 1 |
| Arjona Ferreira, JC; Barzilai, N; Goldstein, BJ; Golm, GT; Guo, H; Kaufman, KD; Marre, M; Sisk, CM | 1 |
| Batty, KT; Ferrari, P; Maker, GL; Olynyk, JK; Siva, B; Trengove, RD | 1 |
| Bakris, GL; Flynn, C | 1 |
7 review(s) available for triazoles and Chronic Kidney Diseases
| Article | Year |
|---|---|
Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence.
Topics: Anemia; Erythropoietin; Hematinics; Humans; N-substituted Glycines; Prolyl-Hydroxylase Inhibitors; Pyridines; Renal Insufficiency, Chronic; Triazoles | 2022 |
Enarodustat: First Approval.
Topics: Anemia; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Molecular Structure; N-substituted Glycines; Prolyl-Hydroxylase Inhibitors; Pyridines; Renal Insufficiency, Chronic; Republic of Korea; Triazoles; United States | 2021 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Pyrazines; Renal Insufficiency, Chronic; Severity of Illness Index; Sitagliptin Phosphate; Triazoles | 2013 |
Deferasirox nephrotoxicity-the knowns and unknowns.
Topics: Acute Kidney Injury; Benzoates; Deferasirox; Glomerular Filtration Rate; Humans; Iron Chelating Agents; Iron Overload; Renal Insufficiency, Chronic; Transfusion Reaction; Triazoles | 2014 |
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Topics: Anemia; Barbiturates; Clinical Trials as Topic; Enzyme Inhibitors; Erythropoietin; Glycine; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Isoquinolines; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2017 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
14 trial(s) available for triazoles and Chronic Kidney Diseases
| Article | Year |
|---|---|
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
Topics: Aged; Aged, 80 and over; Anemia; Female; Hematinics; Humans; Male; Middle Aged; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2021 |
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
Topics: Aged; Aged, 80 and over; Anemia; Female; Humans; Male; Middle Aged; Pyrazoles; Renal Insufficiency, Chronic; Treatment Outcome; Triazoles | 2021 |
Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study.
Topics: Aged; Aged, 80 and over; Anemia; Female; Humans; Japan; Male; Middle Aged; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Triazoles | 2021 |
Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study.
Topics: Anemia; Erythropoietin; Hematinics; Hemoglobins; Humans; Japan; Peritoneal Dialysis; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Triazoles | 2022 |
First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
Topics: Administration, Oral; Adult; Anemia; Area Under Curve; Erythropoietin; Half-Life; Healthy Volunteers; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Male; Prolyl-Hydroxylase Inhibitors; Proof of Concept Study; Pyrazoles; Renal Insufficiency, Chronic; Single-Blind Method; Triazoles; Young Adult | 2018 |
A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
Topics: Aged; Aged, 80 and over; Anemia; Dose-Response Relationship, Drug; Double-Blind Method; Erythropoietin; Female; Ferritins; Follow-Up Studies; Hematinics; Hemoglobins; Hepcidins; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Japan; Kidney; Male; Middle Aged; N-substituted Glycines; Placebos; Pyridines; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Triazoles | 2019 |
Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Darbepoetin alfa; Drug Administration Schedule; Epoetin Alfa; Female; Hematinics; Hemoglobins; Humans; Long-Term Care; Male; Middle Aged; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Triazoles | 2019 |
Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.
Topics: Aged; Anemia; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Ferritins; Hemoglobins; Hepcidins; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Male; Middle Aged; N-substituted Glycines; Pyridines; Renal Dialysis; Renal Insufficiency, Chronic; Triazoles | 2019 |
Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.
Topics: Anemia; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematinics; Humans; Japan; Male; Middle Aged; Prospective Studies; Pyrazoles; Renal Insufficiency, Chronic; Treatment Outcome; Triazoles | 2019 |
Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies.
Topics: Adult; Anemia; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hematinics; Humans; Male; Practice Guidelines as Topic; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Triazoles | 2019 |
Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Basic Helix-Loop-Helix Transcription Factors; Double-Blind Method; Female; Hematinics; Hemoglobins; Hepcidins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Iron; Male; Middle Aged; Prolyl-Hydroxylase Inhibitors; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2019 |
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
Topics: Aged; Blood Glucose; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Placebos; Pyrazines; Renal Insufficiency, Chronic; Severity of Illness Index; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.
Topics: Body Weight; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Pyrazines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles | 2013 |
Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.
Topics: Aged; Anemia, Iron-Deficiency; Area Under Curve; Benzoates; Biological Availability; Chromatography, Liquid; Deferasirox; Drug Administration Schedule; Drug Monitoring; Female; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Pilot Projects; Renal Dialysis; Renal Insufficiency, Chronic; Tandem Mass Spectrometry; Triazoles; Western Australia | 2013 |
14 other study(ies) available for triazoles and Chronic Kidney Diseases
| Article | Year |
|---|---|
The prolyl hydroxylase inhibitor molidustat fails to restore erythropoietin production in the fibrotic kidney.
Topics: Erythropoietin; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Kidney; Prolyl-Hydroxylase Inhibitors; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2022 |
Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
Topics: Animals; Apoptosis; Cell Line; Cytokines; Disease Models, Animal; Fibrosis; Hypertrophy, Left Ventricular; Hypoxia-Inducible Factor 1, alpha Subunit; Inflammation Mediators; Kidney; Male; Mitochondria, Heart; Myocytes, Cardiac; N-substituted Glycines; Neovascularization, Physiologic; Prolyl Hydroxylases; Prolyl-Hydroxylase Inhibitors; Pyridines; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Signal Transduction; Triazoles; Ventricular Function, Left; Ventricular Remodeling | 2020 |
The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.
Topics: Anemia; Animals; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Mice; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2021 |
Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotally nephrectomized rats.
Topics: Animals; Blood Pressure; Disease Models, Animal; Hypertension; Male; Nephrectomy; Prolyl-Hydroxylase Inhibitors; Pyrazoles; Rats, Wistar; Renal Insufficiency, Chronic; Sodium; Triazoles | 2021 |
Axl-inhibitor bemcentinib alleviates mitochondrial dysfunction in the unilateral ureter obstruction murine model.
Topics: Animals; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Citric Acid Cycle; Fatty Acids; Male; Mice; Mice, Inbred C57BL; Mitochondria; Oxidative Phosphorylation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Receptor Protein-Tyrosine Kinases; Renal Insufficiency, Chronic; Triazoles; Ureteral Obstruction | 2021 |
Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies.
Topics: Anemia; Hemoglobins; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Japan; N-substituted Glycines; Pyridines; Renal Dialysis; Renal Insufficiency, Chronic; Triazoles | 2022 |
Enarodustat to treat anemia in chronic kidney disease.
Topics: Anemia; Erythropoietin; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; N-substituted Glycines; Pyridines; Renal Insufficiency, Chronic; Triazoles | 2021 |
Urinary tract aspergillosis in a patient with chronic kidney disease.
Topics: Antifungal Agents; Aspergillosis; Combined Modality Therapy; Diagnosis, Differential; Humans; Immunocompromised Host; Male; Middle Aged; Renal Insufficiency, Chronic; Triazoles; Urinary Tract Infections | 2017 |
Activation of platelet-activating factor receptor exacerbates renal inflammation and promotes fibrosis.
Topics: Animals; Azepines; Collagen; Disease Models, Animal; Fibrosis; Kidney; Mice; Mice, Inbred BALB C; Mice, Knockout; Nephritis; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Renal Insufficiency, Chronic; Triazoles; Ureteral Obstruction | 2014 |
Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
Topics: Administration, Oral; Adult; Aged; Anemia; Benzoates; Chelation Therapy; Deferasirox; Female; Hematopoiesis; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2015 |
Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.
Topics: Anemia; Animals; Erythropoietin; Female; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Macaca fascicularis; Male; Pyrazoles; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Triazoles; Up-Regulation | 2014 |
Association between renal iron accumulation and renal interstitial fibrosis in a rat model of chronic kidney disease.
Topics: Animals; Benzoates; Blood Pressure; Deferasirox; Fibrosis; Gene Expression; Iron; Iron Chelating Agents; Kidney; Male; Nephrectomy; Nephritis, Interstitial; Proteinuria; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Triazoles | 2015 |
Uric acid, indoxyl sulfate, and methylguanidine activate bulbospinal neurons in the RVLM via their specific transporters and by producing oxidative stress.
Topics: Animals; Anion Transport Proteins; Benzoxazoles; Enzyme Inhibitors; Indican; Medulla Oblongata; Membrane Glycoproteins; Membrane Potentials; Methylguanidine; NADPH Oxidase 2; NADPH Oxidase 4; NADPH Oxidases; Neurons; Neuroprotective Agents; Neurotoxins; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Oxidative Stress; Patch-Clamp Techniques; Rats, Wistar; Renal Insufficiency, Chronic; Sympathetic Nervous System; Triazoles; Uric Acid | 2015 |
Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Calcineurin Inhibitors; Diet, Sodium-Restricted; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Fibrosis; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Immunosuppressive Agents; Kidney; Male; Oxidative Stress; Random Allocation; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Tacrolimus; Triazoles | 2015 |